Analyst Report: ELV

1. EXECUTIVE SUMMARY

Shares of Elevance Health, Inc. (NYSE: ELV) surged 5.41% ($21.36) to close at $416.54 on September 10, 2026, driven by a Form 8-K SEC filing reaffirming full-year 2026 earnings guidance alongside reassuring comments from management at the Wells Fargo 21st Annual Healthcare Conference. The health benefits giant reaffirmed its target for FY2026 adjusted shareholders' earnings of at least $27.00 per diluted share and maintained its benefit expense ratio (Medical Loss Ratio or MLR) target of 90.2% ± 50 bps. Crucially, Chief Financial Officer Marc Kaye noted that Q3 2026 adjusted earnings are tracking ahead of internal expectations, assuaging institutional fears regarding run-away medical cost utilization in Medicaid and commercial segments. This guidance confirmation provides market relief, validating Elevance's capacity to restore operating margins through strategic rate hikes, Medicare Advantage restructuring, and exit from unprofitable Medicaid contracts.

2. THE CATALYST (CRITICAL)

The rally on September 10, 2026, was directly triggered by a combination of official corporate regulatory filings and executive conference commentary:

• SEC Form 8-K Filing (Item 7.01): Filed at 6:03 AM EDT on September 10, 2026, Elevance Health disclosed that executive management will reiterate full-year 2026 guidance in upcoming investor meetings.
  • GAAP EPS Floor: Reaffirmed at at least $20.10 per diluted share, incorporating ~$6.90 per share of net unfavorable non-recurring items.
  • Adjusted EPS Floor: Reaffirmed at at least $27.00 per diluted share (ex-unfavorable items), topping Wall Street consensus expectations of $26.91. The filing confirmed no additional net unfavorable adjustments have developed since Q2 2026 results.
  • Benefit Expense Ratio (MLR): Held steady at 90.2% ± 50 bps.
• Wells Fargo 21st Annual Healthcare Conference Commentary: Speaking on September 10, 2026, CFO Marc Kaye informed institutional investors that Q3 2026 adjusted EPS is tracking ahead of prior management forecasts. Management elaborated that efforts to fix underperforming lines—specifically exiting loss-making Medicaid markets (e.g., Washington, D.C.) and narrowing Medicare Advantage offerings toward high-performing Special Needs Plans (D-SNP) and HMOs—are taking hold faster than expected.
• Ex-Dividend Milestone: September 10, 2026, also marked the ex-dividend date for ELV's quarterly payout of $1.72 per share (payable September 25, 2026).

3. COMPANY PROFILE

4. DEEP DIVE ANALYSIS

Fundamental Justification vs. Overreaction

The +5.41% single-day move is fundamentally justified. Managed Care Organizations (MCOs) have suffered elevated valuation discounts throughout 2025–2026 due to industry-wide medical cost inflation (specialty pharmacy, GLP-1s, outpatient surgery) and severe Medicaid margin compression (projected at -1.75% for FY26). Investor anxiety was heightened by Independent Dispute Resolution (IDR) arbitration rulings favoring healthcare providers ~85% of the time at ~8x in-network rates.

Elevance's explicit guidance reaffirmation under Form 8-K removes a major dark cloud heading into Q3 earnings season. It signals that cost trends are contained within the 90.2% MLR guidance band and confirms that underlying core earnings ($27.00/share) remain intact without requiring secondary guidance downward revisions.

Elevance Health (ELV) - Earnings & Guidance Bridge (FY 2026)
----------------------------------------------------------------------
GAAP Shareholders' EPS (Floor):                ≥ $20.10
(+) Cumulative Net Unfavorable Items (Q2):       ~$6.90
----------------------------------------------------------------------
Adjusted Shareholders' EPS (Floor):            ≥ $27.00
Consensus Wall Street Estimate:                 $26.91
----------------------------------------------------------------------
Benefit Expense Ratio (MLR Target):            90.2% (±50 bps)

Peer Comparison & Industry Context

While competitors like Humana (HUM) and Centene (CNC) continue to struggle with government-sponsored member acuity mismatches and Medicare Advantage Star Rating headwinds, Elevance has taken decisive operational steps:

1. Medicaid Retrenchment: Exiting structural loss markets like Washington, D.C. Medicaid while recalibrating state contracts.
2. Medicare Advantage Re-Underwriting: Pivot toward dual-eligible special needs plans (D-SNP) and HMOs with disciplined benefit design.
3. Carelon Expansion: Growth in pharmacy benefit management (CarelonRx) and clinical analytics (HealthOS platform) provides high-margin fee revenue to buffer insurance underwriting risks.

Strategic Bull vs. Bear Case

• Bull Case:

  • Margin Recovery: Re-pricing of commercial and Medicare Advantage books in 2027 will restore net operating margins from current suppressed levels (~2.5% TTM vs 3.2% historical average) back to baseline.
  • Carelon Growth Momentum: CarelonRx and Carelon Services continue expanding contract volume across third-party payers.
  • Valuation Margin of Safety: At ~14.1x Forward P/E (below historical 5-year average of 17.9x), ELV trades at a ~13.8% discount to intrinsic fair value estimates ($483.43).

• Bear Case:

  • IDR Arbitrations & Provider Claims: High provider victory rates in arbitration maintain pressure on commercial outpatient claim costs.
  • Medicaid Redetermination Lag: Until state rate adjustments align with post-redetermination member acuity, Medicaid operating losses (-1.75% FY26 target) remain a drag.
  • Regulatory Scrutiny: Heightened PBM transparency legislation could constrain CarelonRx fee margins.

5. TECHNICAL SNAPSHOT

Price Trend: Strongly Bullish (Trading near 52-Week Highs)
======================================================================
Closing Price (Sep 10, 2026):   $416.54 (+5.41%)
Session Low / High:             $406.00 / $421.90
Volume / 90-Day Avg:            1.90M vs. 1.44M (High Demand)
======================================================================
Key Technical Levels:
- Resistance 2:                 $436.24 (52-Week High - July 14, 2026)
- Resistance 1:                 $421.90 (Sep 10 Intraday High)
- Immediate Support:            $406.00 / $407.38 (Gap Low / Sep 10 Open)
- Major Support:                $395.18 (Sep 9 Closing Price / Gap Fill)
======================================================================
Moving Averages:
- 20-Day Moving Average:        ~$400.50 (Price +4.0% above)
- 50-Day Moving Average:        ~$391.20 (Price +6.5% above)
- 200-Day Moving Average:       ~$359.00 (Price +16.0% above)

• Chart Pattern: ELV executed a clean breakout gap-up off the $395 level, supported by a bullish golden cross setup where the 10-day MA is trending sharply above the 50-day MA.
• Volume Confirmation: Session volume swelled to 1.9M shares traded (vs. 1.44M 90-day average), indicating institutional accumulation rather than retail retail drift.

6. RISK FACTORS

1. Medical Utilization Volatility: Unexpected spikes in Q4 elective outpatient procedures, specialty oncology therapies, or GLP-1 utilization could push the MLR toward the high end of the 90.7% band.
2. Medicaid Acuity Mismatch: Delay in state rate updates relative to actual medical utilization in remaining state Medicaid contracts.
3. Upcoming Catalysts to Watch:
   • Oppenheimer Healthcare Conference: Management fireside chat on September 15, 2026.
   • Q3 2026 Earnings Announcement: Scheduled for October 21, 2026 (Consensus EPS estimate: $4.70 GAAP / Q3 tracking ahead).

7. ACTIONABLE OUTLOOK

• Short-Term (1–2 Weeks): Consolidation / Moderate Upside. Expect ELV to trade in the $410.00 – $425.00 corridor as the market digests the guidance reaffirmation ahead of the September 15 Oppenheimer conference. Any brief pullback to fill the $406–$407 gap represents a tactical entry point.
• Medium-Term (1–3 Months): Target $440.00 – $460.00. Strong Q3 earnings execution on October 21 will serve as the next primary driver to push shares past the 52-week peak of $436.24 toward consensus analyst targets ($457–$475).
• Long-Term Thesis: Strong Overweight / Buy. Strategic realignment away from non-performing Medicaid geographies, coupled with double-digit growth in Carelon capabilities, solidifies Elevance's earnings compounding capability toward $27.00+ adjusted EPS in FY26 and >$30.00 in FY27.